Kendle has named John F. Ameling director, clinical, regulatory and strategic operations, responsible for advising clients on drug development strategies designed to obtain approval of new applications. He will also lead project teams in the preparation of submissions to the FDA. Prior to joining the company, Mr. Ameling worked as an independent regulatory consultant, assisting his clients with designing drug development strategies, including the regulatory filing of INDs and NDAs. Prior to that...